The potency of vecuronium was reported to be greater in Montreal than (28,5 5:6,8 In 1969, Katz et al. ~ reported that the maximum blockade attained after a single dose of d-tubocurarine or sueeinylcholine was greater and the duration of action was longer in New York than in London. The study was performed before dose-response techniques became common practice in the evaluation of muscle relaxants, and before a standard mode of stimulation, the train-of-four, 2 was introduced into clinical use and research.
entre les deux endroits. Dans chaque ville, on a recrutE vingt adultes (dix hommes et dix femmes), agds de 18 gt 65 ans, et anesthdsiEs au thiopentone, protoxyde d'azote (60-70%) et isoflurane (0.5% tdld-expiratoire). On a stimuld le nerf cubital toutes les 20 sec en utilisant le train-de-quatre et on a mesurE la force de contraction de l'adducteur du pouce. Une dose de 0,1 rag" kg -1 de vkcuronium a dtd injectde, suivie de ndostigmine, 0,04 mg" kg -t et d'atropine, 0,02 mg" kg -t lorsque le premier dldment du train-de-quatre rdcupdrait ~ 25% de sa valeur initiale.L'intervalle entre l~njection et le bloc maximum dtait de (moyenne • ET) 3,9 5:1,3 min~ Paris et 4,5 + 1,3 min~ Montrdal (NS). La dur~e d'action, c'est-~-dire le temps entre l'injection de vEcuronium et la rdcupdration de 25%, dtait plus courte h Paris (28,5 5:6,8 min) qu'h Montrdal 09,1 5: 7,3 min) (P < 0,0001). Aprds administration de nEostigmine, il fallait 6,3 5:2,2 min ?t Paris pour atteindre un rapport quatribme: premidre rdponse de 70%, et 5,6 d: 1,9 rain gl MontrEal (NS). On en conclut que la durEe d'une dose ~ d'intubation i> est plus longue d MontrEal, mais que si la ndostigmine est donnde quand la rEcupdration atteint 25%, elle est tout aussi efficace ~ Montrdal qu~ Paris.
In 1969, Katz et al. ~ reported that the maximum blockade attained after a single dose of d-tubocurarine or sueeinylcholine was greater and the duration of action was longer in New York than in London. The study was performed before dose-response techniques became common practice in the evaluation of muscle relaxants, and before a standard mode of stimulation, the train-of-four, 2 was introduced into clinical use and research.
Recently, Fiset et al. 3 performed another transatlantic study, and compared the dose-response curves for vecuronium between Montl~al and Paris. In spite of similar demographic data in both centres and an identical anaesthetic and neuromuscular technique, the Paris doseresponse curve was shifted to the fight by 30%, that is, vecuronium was more potent in Montreal. The difference could not be explained by differences in age, sex, weight or body habitus, because these variables were similar in both cities. Disposition of the drug probably had little effect on these differences, because dose-response data are CAN J ANAESTH 1994 / 41: 10 / pp908-12 obtained from twitch depression obtained shortly after drug administration. Thus, it is possible that the transatlantic differences might be due to a different relationship between plasma concentration and twitch height, i.e., a pharmacodynamic difference.
These data do not necessarily imply that onset is longer and duration is shorter in Paris than in Montrtal, because pharmacokinetic differences could be present. It is also unclear whether differences in sensitiyity extend beyond the dose range (0.02-0.04 mg. kg -l) used for doseresponse data, and also apply to intubating doses (0.1-0.15 mg-kg-l). In addition, differences in sensitivity to vecuronium could also imply differences in the response to neostigmine. Therefore, this study was designed to examine the neuromuscular effects of clinically useful doses of vecuronium and neostigmine under identical anaesthetic conditions in Montrtal and in Paris.
Methods
The protocol was approved by the Ethics Committee at the Royal Victoria Hospital in Montrtal, and at Institut Gustave Roussy in Villejuif, located in the suburbs of Paris, France. At each centre, an equal number of men and women, ASA status I or II, aged 18-65 yr, and scheduled for elective surgery requiring tracheal intubation, were entered in the study. There was a total of 40 patients, 20 from each location. Exclusion criteria were ASA status III or greater, emergency surgery, anticipated difficulty with the airway, deviation from ideal body weight by more than 30%, renal, hepatic or neuromuscular disease, and acute or chronic ingestion of drugs for which an interaction with neuromuscular function is known or suspected. Premedication, when given, consisted of an opioid or a benzodiazepine, and was at the discretion of the anaesthetist.
In the operating theatre, standard monitoring equipment was used and consisted of ECG, pulse oximetry, non-invasive arterial blood pressure measurement, endtidal PCO2, inspired oxygen fraction and end-tidal vapour pressure. Surface electrodes were applied to the ulnar nerve at the wrist and the force of contraction of the adductor pollicis muscle was measured with a Grass FT-10 transducer (Grass Instruments, Quincy, Mass, USA) in Montrtal and a Bioindustry Curamttre transducer (Bioindustry, Boulogne-sur-Mer, France) in Paris. Anaesthesia was induced with thiopentone, 5-7 mg-kg -~, and fentanyl, 1-2 )~g. kg -l,/v. Then, the lungs were ventilated manually with 100% oxygen. Supra-maximal train-offour stimulation was applied after loss of consciousness, using a Datex NMT-221 (Datex, Helsinki, Finland) in Montrtal, and a Bioindustry Curamttre in Paris, alter the calibration of the stimulators was made. Within two minutes after calibration was obtained, vecuronium, 0.1 mg. kg-I was injected/v as a rapid bolus. Tracheal intubation was performed when maximum blockade was obtained. Then, mechanical ventilation was initiated, and adjusted to keep end-tidal PCO2 in the range 30-35 mmHg.
Anaesthesia was maintained with nitrous oxide (60-70%), isoflurane, 0.5% end-tidal concentration, and fentanyl, 1-2 I~g" kg-J as required. No incremental doses of vecuronium were administered. When fast twitch height (Tl) in the train-of-four reached 25% of prevecuronium control, neostigmine, 0.04 mg. kg -I, with atropine, 0.02 mg. kg -I was injected /v. Neuromuscular blockade was monitored for an additional ten minutes, during which time the end-tidal nitrous oxide and isoflurane concentrations were maintained constant.
Times from vecuronium injection to 50%, 95% and maximum Tz blockade were recorded. Times to 50% and 95% were interpolated if necessary. Maximum blockade was considered to occur at the last of three consecutive equal T l responses. With 100% blockade, maximum blockade was considered to take place at the last undetectable train-of-four response. Maximum blockade, duration from injection to 5% and 25% Ti recovery, and duration from 5% to 25% were measured. The train-offour ratio (T4/TI) was measured at 0, 2, 5 and 10 rain after neostigmine administration. In addition, the time from injection of neostigmine to T4/TI = 70% was noted. All measurements were recorded at each site and the tracings were subsequently reviewed by a single investigator (FD). Results are presented as mean -1-standard deviation (SD) and range as indices of dispersion. A Student's t test was applied to comparisons between the two sites and differences associated with a P value <0.05 were considered to be significantly different.
Results
Demographic data are presented in Table I . There were no differences in sex distribution, height and weight between both centres.
Onset times to 50%, 95% or maximum blockade were not different between both cities (Table II) . Maximum blockade was 100% in all Montrtal patients, and in 18 (95%) patients in Paris. The remaining two patients had blockades of 98 and 99%, respectively.
Times to 5% and 25% Tl recovery were respectively 10.8 and 10.6 min longer in Montrtal (P < 0.0001), but the recovery rate (5-25% Ti) was the same at both sites (Table III) .
The train-of-four ratios before, and 2, 5 and 10 min after neostigmine administration were similar in both cities. Mean time from injection of neostigmine to T4/T~ = 70% was approximately six minutes in both centres (Table IV) . 
Discussion
This study shows that the duration of action of vecuronium is longer in Montrtal than in Pads. However, when neostigmine was given at the same level of recovery, its effect was the same at both sites. Onset data were more variable than duration measurements, and this probably explains the lack of differences in onset times. The coefficient of variation (standard deviation as a percentage of mean values) was 30-33% for time to maximum blockade and 18-24% for duration. The anaesthetic technique and neuromuscular monitoring were the same for both centres, and they were intended to mimic clinical conditions. Vecuronium was CANADIAN JOURNAL OF ANAESTHESIA given shortly after induction, and the dose chosen, 0.1 mg. kg -t, is administered commonly for tracheal intubation and for maintenance of relaxation during the fast 30-45 min of surgery. The shorter duration observed in Paris suggests that the relative resistance recorded earlier with dose-response curves using doses in the range 0.02-0.04 mg. kg -I also applies to larger doses more commonly used in clinical practice.
Care was taken to control for the various factors which might influence the onset time or duration of neuromuscular blockade. The mode of stimulation and interval between train-of-four patterns was the same. The time between the start of stimulation and injection of the neuromuscular blocker can influence onset time, and to a lesser extent, duration of action. 4 To avoid this confounding factor, vecuronium was injected shortly (approximately two minutes) after the start of stimulation. The anaesthetic agents were the same in both centres. Endtidal isoflurane concentration (0.5%) was measured and kept constant until at least ten minutes after neostigmine administration. The same muscle, the adductor pollicis, was monitored in both locations, and force of contraction was measured in both instances. Both force transducers had a linear response with an accuracy of approximately + 2%. Thi's possible error might be sufficient to affect measurement of time to 100% blockade, because blockade changes slowly when it approaches 100%. 5,6 For this reason, onset times to 50% and 95% are probably more reliable. These two measures of onset time were not different between both centres. Duration data are even less likely to be affected by a measurement error. When the TI of Paris patients had recovered to 25% of control (at a mean time of 28.5 min), subjects studied in Montrtal had reached less than 5% (which was attained at 31.6 min). Such a discrepancy cannot be attributed to the inaccuracy of measuring devices.
No attempt was made to keep core, muscle or skin temperature at any pre-determined level, thus mimicking clinical conditions. Core temperature was not measured systematically in all patients, and was found to be 30-45 min after induction of anaesthesia, 35.5-36.5~ in both centres. Thus, although mild core hypothermia (34-35 ~ C) might prolong the duration of action of vecuronium, 7 it is unlikely to have been a factor in the present study. Such levels of hypothermia were obtained only after 45-60 min of active cooling. 7 It is unlikely that the transatlantic differences reported here are due to differences in the rate of distribution or elimination of vecuronium. Dose-response relationships depend on the initial concentration of the drug, and are relatively independent of disposition processes, unless these are very rapid. A previous study 3 performed in the same hospitals showed a different dose-response curve. In addition, the rate of recovery from 5 to 25% T~, which reflects the rate of redistribution metabolism and/or elimination of the drug, was the same at both centres, suggesting that altered elimination and/or redistribution are not responsible for the differences in duration. A 30% difference in the dose-response relationships 3 and a 10.6 min in duration (this study) could be both explained by a difference in the plasma concentration vs effect relationship. Pharmacokinetic studies conducted on both sides of the Atlantic Ocean 8,n indicate that plasma concentrations decrease by approximately 30% between 28.5 and 39.1 min, i.e., the times corresponding to return of 25% T~ in Paris and Montrtal respectively. Thus, both the increased duration and increased potency observed in Montrtal could be explained by a concentration response relationship shifted to the left. It remains to be seen whether these differences are due to the changes in protein binding, or to true differences in sensitivity at the neuromuscular junction. Such a study would require simultaneous measurement of vecuronium concentrations, both total and free, and twitch height. Given the inter-patient variability, such a pharmacokineticpharmacodynamic study would require a large number of patients.
The duration of action of vecuronium is affected by many factors, such as age, n weight, m4 pregnancy ~536 and end-organ function. 9,~0 The patients in our study had normal renal and hepatic function, were non-pregnant and had comparable heights and weights. The Montrtal subjects were six years younger than the Paris patients. If anything, this should have produced a shorter duration in Montrtal. The opposite was observed. The presence of a small end-tidal concentration of isoflurane probably had little effect, because the volatile agent did not have time to equilibrate with muscle tissue. ~7 A survey of the literature suggests that the duration of action of vecuronium, 0.1 mg. kg-~, might be more variable with geographical location than the differences between Paris and Montrtal might indicate. In non-pregnant, ASA I or II young to middle-aged adults, the duration to 25% T l recovery was reported to be 26-30 rain in Holland, 17 32 rain in Austria, |6 and 27.6 min in Norway, Is close to the value of 28.5 min reported here for Paris. Durations for the same vecuronium dose given to young adults in North America are somewhat more variable, ranging from 32-37.6 min in New York n-~4 to 50-54 rain in California 9'10 (interestingly, 34 min was reported from the same institution, 7 but from a limited number of subjects No difference in onset time could be demonstrated in this study. This is probably because onset times are more variable than durations and because increasing the dose does not change onset time markedly. For example, in one study, Is increasing the dose by 50%, from 0.I mg-kg-I to 0.15 mg-kg-I decreased onset time from 169 to 146 sec, and the difference was not statistically significant. In Montrtal, the potency of vecuronium was found to be 30% greater than in Paris, suggesting that the effect of the drug might mimic, in Montrtal, that of a dose increased by 30% in Paris. This small increase in equivalent dose would be expected to produce little change in onset times.
There are few studies of the effect of neostigmine, 0.04 mg. kg-t, given at 25% first twitch height recovery after vecuronium. The values of train-of-four ratio reported here for five and ten minutes (68-69% and 81-82% respectively) compare well with the 82 and 84% reported by a Belgian group 2~ at six and nine minutes respectively under nitrous oxide-narcotic anaesthesia. Addition of 1 MAC isoflurane was found to decrease the T4/Tt values by 10-15%. 21 In the present study, approximately 0.4 MAC isoflurane was used, and the results are between those obtained with nitrous oxide-narcotic and nitrous oxide-isoflurane anaesthesia. 2j The effect of neostigmine given at the same twitch height recovery was the same in Montrtal and in Paris. This suggests that acetylcholinesterase function and the other mechanisms responsible for reversal of neuromuscular blockade operate similarly at both sites.
In summary, after an intubating dose of vecuronium, Montrtal patients behave as if they were more sensitive to the drug than subjects with comparable demographic characteristics in Paris and duration of action is increased. Slight alterations in dosage and management of relaxation might be required. For example, all Paris patients recovered to 25% Tj within 45 min while this level of recovery was not attained in 25% of Montrtal patients. There is, however, no need to modify the dose of neostigmine depending on the site, provided the anticholinesterase drug is administered at 25% recovery.
